ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Multimodal Multiorgan-on-a-Chip Platform for Probing Liver-Tumor Interactions and Advancing Prodrug Screening.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To advance the development of microphysiological systems with enhanced metabolic fidelity, there is a critical need to recapitulate native three-dimensional multicellular architecture, enabling non-invasive, multi-parameter measurements. Here, we present a multimodal multi-OoC platform designed to investigate liver-tumor interactions and streamline prodrug screening. The platform features a sophisticated microfluidic circuit with pneumatically actuated valves for dynamic perfusion and strategically configured microwell arrays that support the formation and maturation of 3D hepatic constructs. By synergistically incorporating real-time electrochemical sensing with automated solid-phase microextraction coupled to mass spectrometry (SPME-LC-MS) for pharmaceutical kinetic analysis, the platform allows nonintrusive, longitudinal monitoring of prodrug metabolism. We further implemented an impedance-based immunosensor for real-time assessment of drug-induced hepatotoxicity, quantifying secreted albumin across clinically relevant concentrations (1-80 µM). As proof of concept, we evaluated the metabolic activation and subsequent antineoplastic efficacy of two prodrugs, capecitabine and tamoxifen, highlighting the system's ability to elucidate hepatic metabolic activation pathways and resultant antineoplastic efficacy. By unifying 3D tissue models with complementary real-time analytical modalities, this work provides a versatile and transformative approach for in vitro drug evaluation and mechanistic organ-organ interaction studies. L. Z. conceived the study. D. W. performed the experiments, analyzed the data, and wrote the manuscript. L. Zhao. wrote and revised the manuscript. X. W., and G. G. helped on revising the manuscript. D. G., M. W., and Y. Z. helped to perform the mass spectrometry testing of the parent drug and its metabolites. T. C. assisted in completing all the work related to the proteomics section. Y. H. and S. B. assisted in the fabrication and characterization of the chip. L. Z. and X. W. supervised the research project. All authors read and approved the final manuscript.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.